Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded-access open-label nilotinib study in adults with imatinib-resistant or imatinib-intolerant chronic myeloid leukemia
2005-001818-41Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of nilotinib in chronic myelogenous leukemia (CML) (3 cohorts), sponsored by Novartis. Primary endpoint: Safety profile of nilotinib. Started Nov 2005; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2005-001818-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001818-41.